source
- Boston Scientific cyberattack likely to have ‘material impact’ on financial resultsThe recent cyberattack on Boston Scientific is looking more serious than the medtech major first thought, with the company predicting a possible hit to its third-quarter and full-year results.Fierce Biotech · 1d ago↗ source
- Guardant wins FDA nod for diagnostic guiding use of AstraZeneca’s EtcamahHot on the heels of the approval for AstraZeneca’s breast cancer drug Etcamah, Guardant Health has been given the green light for its companion diagnostic.Fierce Biotech · 1d ago↗ source
- ADARx, backed by AbbVie, files for IPO to fund clinical-stage siRNA programsADARx Pharmaceuticals, a San Diego biotech supported by AbbVie, announced plans to pursue an initial public offering. The company says most of the IPO proceeds will be used to advance three clinic…